Claudia M. Palena
#116,166
Most Influential Person Now
Argentine-American immunologist
Claudia M. Palena's AcademicInfluence.com Rankings
Claudia M. Palenabiology Degrees
Biology
#14451
World Rank
#18206
Historical Rank
#2852
USA Rank
Immunology
#1026
World Rank
#1052
Historical Rank
#109
USA Rank
Download Badge
Biology
Claudia M. Palena's Degrees
- Bachelors Biology University of Buenos Aires
Similar Degrees You Can Earn
Why Is Claudia M. Palena Influential?
(Suggest an Edit or Addition)According to Wikipedia, Claudia M. Palena is an American-Argentine immunologist and cancer researcher. She is head of the immunoregulation section at the National Cancer Institute. Palena researches tumor immunology and cancer immunotherapy.
Claudia M. Palena's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes (2004) (512)
- IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. (2011) (330)
- The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance (2016) (250)
- The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. (2010) (231)
- Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma (2008) (220)
- Homeoboxes in plant development. (1998) (212)
- IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. (2007) (192)
- Chemotherapy‐induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death (2013) (186)
- The Human T-Box Mesodermal Transcription Factor Brachyury Is a Candidate Target for T-Cell–Mediated Cancer Immunotherapy (2007) (157)
- Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. (2012) (142)
- Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. (2019) (140)
- Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances (2020) (133)
- Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors (2019) (126)
- Epithelial-mesenchymal transition and inflammation at the site of the primary tumor. (2017) (119)
- A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells (2017) (114)
- Brachyury, a Driver of the Epithelial–Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer (2012) (114)
- Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models (2019) (110)
- Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases (2015) (102)
- Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. (2017) (97)
- Combination Chemotherapy and Radiation of Human Squamous Cell Carcinoma of the Head and Neck Augments CTL-Mediated Lysis (2006) (86)
- A monomer-dimer equilibrium modulates the interaction of the sunflower homeodomain leucine-zipper protein Hahb-4 with DNA. (1999) (72)
- Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis. (2014) (70)
- Cancer vaccines: preclinical studies and novel strategies. (2006) (69)
- Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. (2020) (69)
- Tumor Plasticity and Resistance to Immunotherapy. (2020) (68)
- The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies (2013) (66)
- Identification of Novel Human CTL Epitopes and Their Agonist Epitopes of Mesothelin (2005) (65)
- WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition. (2014) (63)
- Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine (2013) (62)
- An Autocrine Loop between TGF-β1 and the Transcription Factor Brachyury Controls the Transition of Human Carcinoma Cells into a Mesenchymal Phenotype (2013) (58)
- Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses (2010) (57)
- Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer. (2017) (55)
- A Human Cytotoxic T-Lymphocyte Epitope and Its Agonist Epitope from the Nonvariable Number of Tandem Repeat Sequence of MUC-1 (2004) (53)
- Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury (2017) (48)
- IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib (2016) (48)
- Analyses of Recombinant Vaccinia and Fowlpox Vaccine Vectors Expressing Transgenes for Two Human Tumor Antigens and Three Human Costimulatory Molecules (2005) (47)
- Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity (2020) (44)
- Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas. (2012) (43)
- MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition (2016) (43)
- Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer (2016) (40)
- A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules (2019) (38)
- Combinatorial interactions of two amino acids with a single base pair define target site specificity in plant dimeric homeodomain proteins. (2001) (35)
- Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. (2005) (34)
- Positively charged residues at the N-terminal arm of the homeodomain are required for efficient DNA binding by homeodomain-leucine zipper proteins. (2001) (34)
- New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy (2009) (33)
- A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer (2019) (32)
- Therapeutic cancer vaccines. (2014) (31)
- Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells. (2004) (31)
- Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process. (2014) (31)
- Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells (2011) (31)
- Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies (2016) (31)
- Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death (2013) (27)
- Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer. (2016) (26)
- An immunotherapeutic intervention against tumor progression (2014) (25)
- The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic (2015) (25)
- Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody (2014) (23)
- Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis (2014) (22)
- Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. (2018) (20)
- Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition (2017) (20)
- Identification of cytotoxic T‐lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4) (2007) (20)
- Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients (2009) (20)
- Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy (2019) (19)
- Expression of sunflower homeodomain containing proteins in Escherichia coli: purification and functional studies. (1998) (18)
- Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells. (2010) (17)
- Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7. (2017) (16)
- Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) (2021) (16)
- Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. (2019) (16)
- Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens. (2003) (15)
- The Use of a Humanized NSG-β2m−/− Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa (2020) (15)
- Pharmacological and immunological targeting of tumor mesenchymalization (2017) (13)
- A novel type of dimerization motif, related to leucine zippers, is present in plant homeodomain proteins. (1997) (13)
- Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication (2022) (13)
- Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines. (2015) (13)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Differential gene expression profiles in a human T-cell line stimulated with a tumor-associated self-peptide versus an enhancer agonist peptide. (2003) (11)
- Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer (2021) (11)
- Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer (2021) (9)
- NCI experience using yeast-brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma. (2014) (8)
- Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack (2018) (8)
- The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic (2015) (8)
- T Cell–Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer (2021) (7)
- A phase I study of a yeast-based therapeutic cancer vaccine, GI-6301, targeting brachyury in patients with metastatic carcinoma. (2014) (6)
- A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1. (2003) (6)
- Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy (2021) (6)
- Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies (2022) (4)
- Abstract 1676: Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. (2013) (3)
- Behind the IL-8 ball in prostate cancer (2021) (2)
- Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy (2021) (2)
- The Use of T Cell Costimulation to Enhance the Immunogenicity of Tumors (2014) (2)
- Chapter 20 – Recombinant TRICOM-based Therapeutic Cancer Vaccines: Lessons Learned (2013) (2)
- Abstract OT1-08-01: A phase Ib trial of sequential combinations of BN-brachyury, entinostat, ado-trastuzumab emtansine (T-DM1) and bintrafusp alfa (M7824) in advanced stage breast cancer (BrEAsT) (2020) (2)
- Identification of Novel Human CTL Epitopes and TheirAgonist Epitopes ofMesothelin (2005) (1)
- A rare insight into the immunosuppressive landscape of prostate cancer bone metastases. (2021) (1)
- Upregulation of oncogenic MUC1 by the EMT transcription factor brachyury mediates immunotherapy-resistance in tumor cells (2015) (1)
- Stem cells and cancer immunotherapy: Arrowhead’s 2nd annual cancer immunotherapy conference (2014) (1)
- Generation of human T cells directed against an agonist epitope of Brachyury, a transcription factor involved in human tumor cell epithelial to mesenchymal transition (EMT) (2013) (1)
- antigen-presenting cells avipox-vector infection: an alternative source of efficient Human B cells that hyperexpress a triad of costimulatory molecules via (2013) (1)
- Interleukin-8 drives epithelial-mesenchymal transition of human carcinomas (2013) (1)
- Development of cancer vaccines targeting brachyury , a transcription factor associated with tumor EMT (2017) (1)
- Brachyury, a driver of tumor invasiveness and resistance to multiple therapies, is a novel immunotherapy target (2013) (1)
- Vaccine Therapy and Integration with Other Modalities (2013) (0)
- Abstract CN07-03: Brachyury and the interleukin-8 axis in tumor progression (2018) (0)
- TWO Therapeutic Cancer Vaccines (2014) (0)
- High levels of expression of the transcription factor Brachyury induce resistance of human carcinoma cells to immune-mediated attack (2013) (0)
- An IL-15 superagonist enables anti-tumor efficacy of NK cells against all molecular variants of small cell lung cancer (SCLC). (2022) (0)
- Abstract B04: Multimodal cancer immunotherapy combining IL-8 inhibition, adenovirus vaccine, IL-15 super agonist, and anti-PD-L1/TGFβRII agent reduces mesenchymalization and enhances anti-tumor efficacy (2020) (0)
- 438 Interrogation of immune toxicity in patients with thymic epithelial tumors (TETs) (2022) (0)
- Phase I trial of a modified vaccinia ankara (MVA) priming vaccine followed by a fowlpox virus (FPV) boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors. (2019) (0)
- 570 Blockade of the inhibitory collagen receptor LAIR-1, PD-L1, and TGF-β promotes anti-tumor activity through T cell activation and myeloid cell polarization (2021) (0)
- Abstract A42: MK-1775, a WEE1 inhibitor alleviates resistance to immune attack of tumor cells undergoing an epithelial-mesenchymal transition (2015) (0)
- A phase I study of Ad5 PSA/MUC-1/brachyury vaccine in patients with metastatic castration resistant prostate cancer (mCRPC) (2019) (0)
- Importance of dose scheduling of denileukin diftitox/vaccine combination therapy to reduce T regs and to enhance immune responses (2007) (0)
- A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer. (2021) (0)
- Abstract 4032: Modulation of tumor PD-L1 expression by epithelial-mesenchymal phenotypic plasticity (2016) (0)
- Abstract 611: Reversion of mesenchymal features in NSCLC cells using M7824, a first-in-class bi-functional immunotherapeutic agent targeting PD-L1 and TGFβ1 (TGFβ TRAP) (2017) (0)
- 445 Blockade of the inhibitory collagen receptor LAIR-1 with NC410, a LAIR2-Fc fusion protein, enhances anti-tumor activity of the bifunctional fusion protein bintrafusp alfa (2020) (0)
- encoding for multiple costimulatory molecules (CLL): enhanced immunogenicity of CLL cells via infection with vectors Potential approach to immunotherapy of chronic lymphocytic leukemia (2013) (0)
- CBIO-01. TRANSCRIPTIONAL MODULATION OF BRACHYURY IN CHORDOMA (2017) (0)
- Abstract CN04-01: Targeting the epithelial-mesenchymal transition via brachyury-based cancer vaccines (2015) (0)
- 727 Resistance to enzalutamide and abiraterone drives tumor phenotypic plasticity and resistance to immune-mediated cytotoxicity (2021) (0)
- Abstract CN08-01: IL-8 in tumor progression (2019) (0)
- Development of cancer vaccines targeting brachyury, a driver of the epithelial-mesenchymal transition of human carcinomas (2013) (0)
- The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance (2014) (0)
- Abstract B82: Identification of tumor neoantigens for combination therapy in murine tumor models (2018) (0)
- Recombinant TRICOM-based Therapeutic Cancer Vaccines (2013) (0)
- Abstract 1533: Transcriptional inhibition of brachyury in chordoma is associated with adoption of quiescent phenotype (2017) (0)
- Modification of B-CLL Cells Via Infection with a Replication-Defective MVA Virus Encoding Three Costimulatory Molecules: A Potential Approach to Tumor Cell Immunotherapy of B-CLL. (2004) (0)
- The T-box transcription factor Brachyury controls tumor cell migration and invasion (2008) (0)
- 176 Vector-based Vaccines for Cancer Therapy (2009) (0)
- Countering tumor progression by targeting of a driver of the epithelial-mesenchymal transition (2014) (0)
- Abstract A16: Natural killer cell therapy efficacy is enhanced through inhibition of myeloid-derived suppressor cell trafficking (2020) (0)
- Abstract 278: High levels of expression of the transcription factor Brachyury induce resistance of human carcinoma cells to immune-mediated attack. (2013) (0)
- Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation. (2004) (0)
- Abstract B64: A high-throughput screen identifies fulvestrant as an enhancer of immune-mediated cytotoxicity of mesenchymal-like lung cancer cells (2017) (0)
- An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC (2022) (0)
- Abstract B29: The importance of epitope spreading in the generation of effective antitumor immunity in mice treated with combination immunotherapy (2020) (0)
- Abstract 5540: Tumor phenotypic plasticity and resistance to immune-mediated cytotoxicity in models of castration resistant prostate cancer (2022) (0)
- Abstract 6100: Chemotherapy reduces TGF-beta signaling triggered by blockade of the PD-1/PD-L1 axis (2022) (0)
- Abstract A64: Brachyury-mediated epithelial-mesenchymal transition of human carcinoma cells is associated with an increased resistance to immune-mediated attack (2011) (0)
- Abstract PR20: A novel combination immunotherapy with a vaccine targeting tumor neoepitopes that mediates immune cascade in murine tumor models (2020) (0)
- Abstract C53: Overexpression of Brachyury in human carcinoma cells drives the acquisition of resistance to anticancer therapeutics (2011) (0)
- Stem cells and cancer immunotherapy (2014) (0)
- 909 Overcoming resistance to NK-mediated lysis in enzalutamide-resistant prostate cancer cells (2022) (0)
- Abstract 1260: Generation of human T cells directed against an agonist epitope of a transcription factor involved in epithelial to mesenchymal transition (EMT). (2013) (0)
- Brachyury as a vaccine target for the control of the epithelial-tomesenchymal transition of carcinoma cells (2013) (0)
- Abstract SY24-02: Development of recombinant vaccines for the prevention and therapy of human carcinomas (2011) (0)
- Abstract B43: Simultaneous inhibition of CXCR1/CXCR2, TGF-β, and PD-L1 overcomes immune resistance driven by tumor plasticity (2020) (0)
- In-situ diversification of immunity following vaccination targeting tumor neoepitopes; an integral component of combinatorial immunotherapy (2019) (0)
- Abstract 1489: The T-box transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to chemotherapy and radiation. (2013) (0)
- Therapeutics , Targets , and Chemical Biology WEE 1 Inhibition Alleviates Resistance to Immune Attack of Tumor Cells Undergoing Epithelial – Mesenchymal Transition (2014) (0)
- 710 Differences in the susceptibility of human small cell lung cancer variants to NK cell-mediated lysis can be overcome with the addition of N803 (IL-15 superagonist) (2021) (0)
- Systemic Immune Response in Murine Bilateral Pheochromocytoma Model During Immunotherapy Based on a Combination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibodies (MBTA Therapy) (2021) (0)
- CSIG-05. PUTTING THE BRAKES ON BRACHYURY: IDENTIFYING AND TARGETING A CONSERVED TRANSCRIPTIONAL NETWORK THAT DRIVES PRIMARY AND METASTATIC TUMOR INITIATION AND PROPAGATION (2016) (0)
This paper list is powered by the following services:
Other Resources About Claudia M. Palena
What Schools Are Affiliated With Claudia M. Palena?
Claudia M. Palena is affiliated with the following schools:
